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Abstract
Background: The 2016 ‘Start Free, Stay Free, AIDS Free’ global agenda, builds on the 2011-2015 ‘Global Plan’. It prioritises
22 countries where 90% of the world’s HIV-positive pregnant women live and aims to eliminate vertical transmission of
HIV (EMTCT) and to keep mothers alive. By 2019, no Global Plan priority country had achieved EMTCT; however, 11 non-
priority countries had. This paper synthesises the characteristics of the first four countries validated for EMTCT, and of the
21 Global Plan priority countries located in Sub-Saharan Africa (SSA). We consider what drives vertical transmission of HIV
(MTCT) in the 21 SSA Global Plan priority countries.
Methods: A literature review, using PubMed, Science direct and the google search engine was conducted to obtain
global and national-level information on current HIV-related context and health system characteristics of the first four
EMTCT-validated countries and the 21 SSA Global Plan priority countries. Data representing only one clinic, hospital or
region were excluded. Additionally, key global experts working on EMTCT were contacted to obtain clarification on
published data. We applied three theories (the World Health Organisation’s building blocks to strengthen health systems,
van Olmen’s Health System Dynamics framework and Baral’s socio-ecological model for HIV risk) to understand and
explain the differences between EMTCT-validated and non-validated countries. Additionally, structural equation modelling
(SEM) and linear regression were used to explain associations between infant HIV exposure, access to antiretroviral
therapy and two outcomes: (i) percent MTCT and (iii) number of new paediatric HIV infections per 100 000 live births
(paediatric HIV case rate).
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Results: EMTCT-validated countries have lower HIV prevalence, less breastfeeding, fewer challenges around leadership,
governance within the health sector or country, infrastructure and service delivery compared with Global Plan priority
countries. Although by 2016 EMTCT-validated countries and Global Plan priority countries had adopted a public health
approach to HIV prevention, recommending lifelong antiretroviral therapy (ART) for all HIV-positive pregnant and lactating
women, EMCT-validated countries had also included contact tracing such as assisted partner notification, and had
integrated maternal and child health (MCH) and sexual and reproductive health (SRH) services, with services for HIV
infection, sexually transmitted infections, and viral hepatitis. Additionally, Global Plan priority countries have limited data
on key SRH indicators such as unmet need for family planning, with variable coverage of antenatal care, HIV testing and
triple antiretroviral therapy (ART) and very limited contact tracing. Structural equation modelling (SEM) and linear
regression analysis demonstrated that ART access protects against percent MTCT (p<0.001); in simple linear regression it is
53% protective against percent MTCT. In contrast, SEM demonstrated that the case rate was driven by the number of HIV
exposed infants (HEI) i.e. maternal HIV prevalence (p<0.001). In linear regression models, ART access alone explains only
17% of the case rate while HEI alone explains 81% of the case rate. In multiple regression, HEI and ART access accounts
for 83% of the case rate, with HEI making the most contribution (coef. infant HIV exposure=82.8, 95% CI: 64.6, 101.1, p<
0.001 vs coef. ART access=-3.0, 95% CI: -6.2, 0.3, p=0.074).
Conclusion: Reducing infant HIV exposure, is critical to reducing the paediatric HIV case rate; increasing ART access is
critical to reduce percent MTCT. Additionally, our study of four validated countries underscores the importance of contact
tracing, strengthening programme monitoring, leadership and governance, as these are potentially-modifiable factors.
Introduction
Since 2004, almost all countries globally have successfully
reduced vertical transmission of HIV (MTCT), following a
four-pronged approach developed by the World Health
Organization (WHO) [1, 2] (Fig. 1). This includes prevent-
ing HIV amongst women of reproductive age; reducing
unplanned pregnancy and unmet need for family planning;
providing HIV testing and counselling and specific anti-
retroviral drugs during pregnancy, delivery and breastfeed-
ing for women living with HIV and care, treatment and
support to women living with HIV, and their families [3].
In 2011 the United Nations General Assembly high level
meeting on AIDS launched the ‘Global Plan towards the
Elimination of New HIV Infections Among Children by
2015 and Keeping Their Mothers Alive’ (Global Plan), com-
mitting to reduce the number of new HIV infections
among children by 90% and the number of AIDS-related
maternal deaths by 50%, by 2015 [2, 4, 5]. This Global Plan
prioritized 22 countries (where 90% of the world’s HIV-
positive pregnant women reside) for virtual elimination of
MTCT as a public health problem (EMTCT), including
one country in Asia (India), five countries in West Africa
(Chad, Cameroon, Core d’Ivoire, Ghana, Nigeria), five in
East Africa (Burundi, Ethiopia, Kenya, Uganda and United
Republic of Tanzania), one in Central Africa (Democratic
Republic of Congo) and ten in Southern Africa (Angola,
Botswana, Lesotho, Malawi, Mozambique, Namibia, South
Africa, eSwatini, Zambia and Zimbabwe) [2]. The commit-
ment to EMTCT culminated in the policy transition to
lifelong triple antiretroviral therapy (ART) for all pregnant
and lactating women regardless of their CD4 cell count or
disease staging, known as prevention of MTCT (PMTCT)
Option B+ [6]. In 2016 the Start Free, Stay Free, AIDS Free
global agenda was launched to build on the successes of the
Global Plan [7]. It prioritises preventing new HIV infections
among women and emphasizes retention of HIV-positive
pregnant women and mothers on lifelong ART and early
diagnosis and treatment for HIV-positive infants, children
and adolescents.
PMTCT impact has traditionally been measured
using MTCT at 6 weeks and 18 months postpartum. In
2014, the WHO, in collaboration with the Joint United
Nations Programme on HIV/AIDS (UNAIDS), the
United Nations Population Fund (UNFPA), and the
United Nations Children’s Fund (UNICEF), released
two impact and three process criteria to validate
EMTCT [8, 9]. These should be achieved in at least one
of the lowest subnational levels, e.g. a district for one
(impact criteria) and two years (process criteria), to
validate EMTCT (Fig. 2). The impact validation criteria
focus on virtually eliminating MTCT as a public health
problem, defined as percent MTCT less than 2% or 5%
at final endpoint in non-breastfeeding or breastfeeding
countries respectively, and reducing the case rate of
new paediatric infections to 50 or less per 100 000 live
births.
On June 30, 2015, the WHO announced validation of
EMTCT in Cuba, a non-breastfeeding country [10]. Almost
a year later Thailand, Armenia and Belarus were validated
as having virtually eliminated MTCT as a public health
problem [10, 11]. In 2017, Anguilla, Antigua & Barbuda,
Bermuda, Cayman islands, Montserrat, St Christopher &
Nevis, and in 2018, Malaysia met the EMTCT validation
criteria (https://www.who.int/reproductivehealth/congeni
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tal-syphilis/WHO-validation-EMTCT/en/). In high-income
countries, almost universal early ART coverage amongst
HIV-positive pregnant women and avoiding breastfeeding
have reduced MTCT risk to less than 1%. Despite sub-
stantial progress in low- and middle-income countries,
which are mostly breastfeeding countries, the aggregate
final MTCT at breastfeeding cessation is more than 5%,
with case rates above the targeted 50 per 100 000 live
births [6, 12, 13].
This paper synthesises the characteristics of the first
four countries that met the EMTCT validation criteria
(‘EMTCT-validated countries’), given that they have a
longer history of EMTCT. We juxtapose these against
the characteristics of the 21 Sub Saharan African (SSA)
Global Plan priority countries that have not yet been
EMTCT-validated. We conducted additional mediation
and regression analyses to understand drivers of per-
centage MTCT and the EMTCT case rate, and consider
what it will take for the 21 SSA Global Plan countries to
achieve the EMTCT validation criteria.
Methods
Global and national data published in English were sought
to synthesise HIV- and PMTCT-related characteristics of
EMTCT-validated countries and the 21 SSA Global Plan
priority countries. PubMed, Google scholar and Science
Direct were used to search for relevant peer- reviewed
Fig. 2 WHO criteria for validating elimination of HIV transmission






Fig. 1 Targets for eliminating MTCT and keeping mothers alive
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articles in English, using the terms MTCT, EMTCT and
PMTCT effectiveness. As this paper mainly focuses on
current status and is not a review of progress over many
years, once a document with updated information on a
particular indicator or topic was obtained, no additional
searches were conducted for prior documents on that in-
dicator. Documents or papers that only focused on a sub-
national level such as one clinic, hospital or region were
excluded as information from subnational settings were
not relevant for this synthesis. Additionally, key individ-
uals participating in global think tanks and expert groups
were identified and contacted for relevant global or coun-
try-level reports, data, fact sheets and press releases on
EMTCT or measuring PMTCT effectiveness. Although
the EMTCT criteria specify that all criteria should be met
in at least one of the lowest sub-national levels, this syn-
thesis is restricted to national level, given the dearth of
reliable data at subnational levels in SSA settings [14, 15].
We applied three theories, the WHO’s six building blocks
to strengthen health systems, van Olmen’s Health System
Dynamics framework and Baral’s socio-ecological model
for HIV risk to understand and explain the differences
between EMTCT validated and non-validated countries.
The WHO theory states that strengthening six health sys-
tem building blocks, namely (i) leadership and governance,
(ii) health care financing, (iii) the healthcare workforce,
(iv) medical products and technologies, (v) information
and research and (vi) service delivery improves access,
coverage, quality and safety of interventions, resulting in
improved outcomes including equity, responsiveness and
efficiency [16]. The van Olmen Health Systems Dynamics
framework recognizes the existence of an overarching
context within which health systems function, as well as
the importance of leadership and governance, service
delivery, resources (infrastructure, human resources, fi-
nances and knowledge and information) and population
characteristics on goals and health outcomes [17]. Baral’s
social ecological model acknowledges rings of influence
on HIV risk, beginning at the individual level, expanding
to social and sexual networks, community, public policy
and HIV epidemic stage [18]. We considered these three
models because they each adopt a different approach,
ranging from system-specific [16], system within a context
[17] to individual within a system and context [18]. We
integrated the information from these theories to compare
and understand the EMTCT-validated and SSA Global
Plan priority countries, and consider what it will take to
achieve EMTCT in the latter.
We used both linear regression and Structural Equation
modelling (SEM) to estimate the contribution of infant
HIV exposure (HEI) and ART access to percent MTCT
(%MTCT) and the paediatric case rate (case-rate). The out-
come case-rate was defined as the number of new paediat-
ric HIV cases per 100 000 births, and the outcome
%MTCT was percentage HIV transmission (numerator:
number of new HIV infections amongst infants born to
HIV infected mothers; denominator: number of HIV in-
fected mothers), both assessed for 2017. The main exposure
for both models was infant HIV exposure (HEI), defined as
(number of HIV-positive pregnant women in 2017 *100)/
total number of births in 2017. Due to limitations of sample
size (number of countries), we reduced the number of vari-
ables in the models by creating an “ART-score”. This was
defined as: ART-score = total access to treatment = ART
access = % of HIV-positive on treatment (general popula-
tion) + % HIV-suppressed (general population) + % of preg-
nant women on ART. Prior to deriving the additive score,
we checked for internal consistency in the 3 ART-items
(Cronbanch’s alpha=0.916) and also performed a confirma-
tory factor analysis to check how well the three items were
loading on a single factor (root mean square error of ap-
proximation (RMSEA)<0.05, Tucker and Lewis Index
(TLI)>0.95, comparative fit index (CFI)>0.95, coefficient of
determination (CD)=0.94). We followed published rules of
minimum levels of the fit indices, which specify minimum
requirement for model acceptance for RMSEA values must
be less than 0.06 and for CFIs and TLIs as 0.90 [19]. We
also performed confirmatory factor analysis of the overall
Structural Equation Model to check how well the model fit-
ted the data (RSMEA<0.05, TLI, CFI>0.95, CD=0.88) and
used the Sobel test to test for the significance of the mediat-
ing factor in both the structural equation model and the
linear regression model [20]. For the linear regression
model, we used the ‘product of coefficient’ method to test
the mediation effects [20].
Results
There is a stark contextual difference between EMTCT-
validated countries and the 21 SSA Global Plan priority
countries. These are presented within the three concepts
referred to in the methods.
Dynamic system within a context
Apart from the health system differences between the
EMTCT-validated and 21 SSA Global Plan priority
countries, their general HIV contexts differ considerably:
the former have substantially lower HIV incidence and
prevalence than SSA Global Plan priority countries
(Table 1). Although EMTCT-validated countries have
unknown unmet need for family planning, and low levels
of HIV suppression, they have a low HIV incidence, and
few people living with HIV (Table 1). Furthermore, the
HIV epidemic is concentrated in injecting drug users
(Belarus and Armenia) and men who have sex with men
(Cuba and Thailand), rather than women of reproductive
age, although the Armenian epidemic is increasingly
becoming heterosexual [21–23]. Consequently, the num-
ber of HIV-positive pregnant women is low in EMTCT-
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validated countries with antenatal HIV prevalence at less
than 1.3% across all four countries. The number of
people living with HIV ranges from approximately 3 400
in Armenia to approximately 440 000 in Thailand [24].
Of these four countries, Thailand has the largest HIV
epidemic, close in absolute numbers to Botswana,
Ghana, Cote d’ Ivoire, Angola and the DRC (Table 1). In
contrast, the 21 SSA Global Plan priority countries are
mainly low- or middle-income with an HIV epidemic
driven by heterosexual transmission, and numbers of
people living with HIV ranging from 65 000 in Burundi
to 7800 000 in South Africa (Table 1). Between 2009
and 2015, HIV incidence amongst women in Global Plan
priority countries declined by 5%, rather than the 50%
target and there were 4.5 million (3.8 milion-5.4 million)
newly-infected women of reproductive age in Global
Plan priority countries during this period [25]. South
Africa added the largest number of new HIV infections
in this group (1.2 million) followed by Nigeria (770 000)
and Uganda (350 000)[25] Notwithstanding these chal-
lenges, between 2009 and 2015, the number of children
newly infected with HIV declined by between 21% and
86% in the 21 SSA Global Plan priority countries: ten
countries have reduced MTCT by >66% and seven by
>70%; moreover, collectively these countries have re-
duced new paediatric HIV infections from 270 000
(230000-330000) in 2009 to 110 000 (78000-150 000) in
2015 [25, 26]. This is a significant improvement com-
pared to the 24% reduction measured between 2000 and
2008 [25]. Most of the progress in PMTCT in the 21
SSA Global Plan priority countries occurred during the
last five years; of the 1.4 million new HIV infections
amongst children averted since 2000, 1.2 million were
averted between 2009 and 2015 [25]. According to
UNAIDS 2017 estimates, the final MTCT rate (i.e. mea-
sured at the end of breastfeeding), ranged from 5% in
Botswana to 26% in Angola (Table 2) [3]. However,
because HIV prevalence remains high, the paediatric
HIV case rate, calculated as antenatal HIV prevalence
multiplied by the %MTCT rate multiplied by 100 000
remains above the targeted 50 per 100 000 live births in
many countries, including South Africa (where final
%MTCT is estimated as 5.3%) (Table 2). This illustrates
the role of maternal HIV burden on meeting EMTCT
targets.
System-specific factors relating to the six health system
building blocks
In EMTCT-validated countries, the introduction of life-
long ART for pregnant and lactating women, synonym-
ous with universal test and treat, occurred between 2011
(Cuba) and 2016 (Thailand), and coverage had expanded
to more than 90% by 2016 [10, 11]. In all EMTCT-vali-
dated countries, integration between maternal and child
health (MCH) and sexual and reproductive health (SRH)
services and services for HIV infection, sexually trans-
mitted infections, and viral hepatitis underpins all
PMTCT-related activities [10, 11]. Additionally, HIV
prevention services have a strong contact tracing com-
ponent to prevent ongoing transmission and provide
HIV services to those in need. For example, as early as
1983, the Cuban HIV prevention programme included
contact tracing to identify and treat all people within the
social networks of the HIV-positive person [27]. Further-
more, all health care, including HIV-related care, is free
with an emphasis on prevention and community based
care and empowerment of communities, resulting in
high levels of uptake and adherence [28]. During ante-
natal care, more than ten visits are recommended with
regular HIV testing and partner testing [29]. Addition-
ally, the Cuban health system is constructed around the
primary health care team; each team knows its catch-
ment area, and conducts community-based needs assess-
ments regularly and home visits to improve quality and
coverage of care [28]. Similarly in Thailand, universal
health coverage was achieved in 2002, with the introduc-
tion of short-term ART during breastfeeding, regardless
of CD4 cell count in 2010, and lifelong ART for all
pregnant and breastfeeding women in 2014 [30]. Partner
testing is an integral part of HIV management in
Thailand, and HIV testing rates in the general popula-
tion are more than 90% in three of the four EMTCT-
validated countries. Over the past ten years, EMTCT-
validated countries are less known for crises around
leadership and governance, infrastructure, human re-
sources and service delivery compared with Global Plan
priority countries [30].
All of the 21 SSA Global Plan priority countries had
adopted ART for pregnant and lactating women by 2016,
and most had fully scaled up implementation by the end of
2017 [31]. Additionally, by 2016 most countries had
adopted a ‘treat all’ approach for all persons living with
HIV infection (Table 1). However, in only eight (38%) of
the 21 SA Global plan priority countries, non-disclosure of
HIV status is criminalised, compared with three of the four
(75%) EMTCT-validated countries (Table 1). Despite the
commitment to introduce policies that enable HIV care
and facilitate EMTCT, SSA Global Plan priority countries
have large gaps in basic sexual and reproductive health
services: unmet need for family planning is unknown in
many SSA Global plan countries and variable among those
that report data [3]; country-level coverage of four ante-
natal visits during pregnancy is variable, ranging from 31%
to 87% in SSA Global plan countries, compared with 93-
100% in EMTCT-validated countries (Table 1). Moreover,
data demonstrate that in SSA Global Plan priority coun-
tries, few women receive 4 or more antenatal visits starting
in the first trimester and even fewer receive eight or more
Goga et al. BMC Infectious Diseases 2019, 19(Suppl 1):783 Page 7 of 13
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antenatal visits starting in the first trimester, delaying
PMTCT access [32, 33]. Despite these challenges, the 21
SSA Global Plan countries have adopted increasingly effi-
cacious, evidence-based PMTCT policies, and pooled
coverage of key PMTCT interventions (excluding
single dose nevirapine) in the 21 Global Plan coun-
tries increased from 36% (32-41%) in 2009 to 80%
(71-90%) in 2015 [25]. According to global reports,
six of the priority countries (Botswana, Mozambique,
Namibia, South Africa, eSwatini and Uganda) met the
Global Plan goal of ensuring ≥90% ART coverage
amongst pregnant women living with HIV [26]. How-
ever, viral load monitoring is sub-optimal in all coun-
tries and most countries are unable to provide
disaggregated data to monitor pregnant and breast-
feeding women. Furthermore, health systems within
SSA Global Plan priority countries are plagued by
challenges, and often crises with leadership and gov-
ernance (in the health sector, and in general), infra-
structure, healthcare financing, and availability of
basic medical supplies, which are less prevalent in the
EMTCT-validated countries [34]. These challenges
weaken the health system and compromise service de-
livery, thus hampering further progress and EMTCT
[16, 35].
Individual level - stigma
At the individual level, surveys conducted in Thailand
during 2010 and Belarus during 2013, amongst 233 and
370 people living with HIV, respectively, demonstrated
the existence of self-stigma and external stigma from
others: between 33% to 60% of interviewees reported
self-stigma or being excluded from community or reli-
gious activities because of their HIV status [30, 31]. This
seems similar to the self and external stigma described
in SSA [36]. Thailand, Belarus and South Africa are tak-
ing steps to reduce stigma including advocacy, the
involvement of religious leaders in stigma reduction
training, removing negative portrayal of HIV in the
media and individual support to reduce self-stigma [37].
It is noteworthy that the stigma in SSA Global Plan
priority countries includes more females than in the
EMTCT-validated countries, given the largely heterosex-
ual nature of the epidemic and the larger numbers of
HIV-positive people in SSA; thus gender issues and in-
equality are closely tied to ongoing stigma in SSA [37].
Results of structural equation modelling and linear
regression
SEM analysis demonstrated that in a model that includes
ART access (ART score) as a mediator in the relationship
between HEI and %MTCT, ART score is protective against
%MTCT (mediating effects coefficient: -0.41, 95% confi-
dence interval (CI): -0.61,-0.21, p<0.001, Table 3) explaining
54% of the %MTCT. Linear regression corroborated these
findings. In simple linear regression models, infant HIV ex-
posure alone explains only 8% of the %MTCT and
ART score explains 53% of the %MTCT. In the multivari-
able linear regression model assessing the relationship be-
tween HEI and %MTCT, with ART score as a mediator,
ART score was associated with a lower %MTCT (mediating
effects = -0.38, 95% CI: -0.64, -0.21, p<0.001, Table 3), and
the multivariable regression model with ART score as a
mediator explains 53% of the variation in %MTCT, Table
3 % (adjusted R2=0.53). In this multivariable model, the big-
gest contribution was made by ART score (coefficient -0.11
(95% CI: -0.16, -0.06, p<0.001). Results are different for the
case rate: SEM demonstrated that ART score, as a mediator
between HEI and paediatric case rate, only protected
against 13% of the paediatric case rate and this association
was not significant (indirect effect= -10.6 95% CI -21.8, 1.8,
p=0.077); the case rate was driven by infant HIV exposure
(total effects= 71.6 95% CI 57,9, 85,3, P<0.001). Simple lin-
ear regression models show that ART access alone explains
only 17% of the case rates while infant HIV exposure alone
explains 81% of the case rates. In multiple regression infant
HIV exposure and ART score account for 83% of the case
rate, with infant HIV exposure making the most contribu-
tion (coef. infant HIV exposure=82.8, 95% CI= (64.6,
101.1), p<0.001 vs coef. ART score=-3.0, 95% CI=(-6.2, 0.3),
p=0.074), Table 3.
Discussion
As described above, there are stark differences in the health
systems and overall HIV epidemics in EMTCT-validated
and the 21 SSA Global Plan priority countries. Noting these
differences, we discuss what it would take for 21 SSA
Global Plan priority countries to eliminate MTCT.
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EMTCT requires prevention or early diagnosis of mater-
nal HIV infection, immediate initiation of ART amongst
HIV-positive women, post-natal infant prophylaxis and
maternal viral suppression pre-conception, antenatally and
during breastfeeding [6, 38]. Population-level data demon-
strate that MTCT decreased to <1.2% when mothers
initiated ART pre-conception, emphasising the importance
of pre-conception test and treat strategies amongst women
of reproductive age [39]. Meticulous patient tracking to
reduce drop-out from care reduces MTCT but more
importantly eliminating missed opportunities for diagnosing
maternal HIV-infection leads to the largest drop in MTCT
Table 3 Structural equation modelling and mediation analysis to estimate the contribution of infant HIV exposure and ART score to
%MTCT and the paediatric case rate
Main outcome: %MTCT
a) Structural equation model
Path Coef (95%CI) Standardized coef p-value
Direct effects HEI → % MTCT 0.11 (-0.15, 0.37) 0.15 0.398
ART_score → % MTCT -0.11 (-0.15, 0.08) -0.85 <0.001
HEI → ART_score 3.64 (2.27, 5.02) 0.63 <0.001
Indirect (mediation) effectb HEI → % MTCT -0.41 (-0.61, -0.21) -0.54 <0.001
Total effects HEI → % MTCT -0.30 (-0.54, -0.05) -0.39 0.018
ART_score → % MTCT -0.11 (-0.15, -0.08) -0.85 <0.001
HEI → ART_score 3.65 (2.27, 5.02) 0.63 <0.001
b) Linear Regression model
Model independent variable outcome Coef (95% CI) Standardized coef. (Adjusted R2) p-value
Simple linear HEI % MTCT -0.27 (-0.58, 0.04) -0.35 (0.08)* 0.089
ART_score % MTCT -0.10 (-0.14, -0.06) -0.74 (0.53)* <0.001
HEI ART_score 3.39 (1.41, 5.36) 0.60 (0.34)* 0.002
Multiple regression HEI
ART_score
% MTCT 0.11 (-0.17, 0.40) 0.15.a 0.418
%MTCT -0.11 (-0.16, -0.06) -0.85 (0.53a) <0.001
Mediated effectsb HEI % MTCT -0.38 (-0.64, -0.21) <0.001
Main Outcome: Paediatric case rate (case-rate)
a) Structural equation model
Effect Path Coef (95%CI) Standardized coef p-value
Direct effects HEI → Case_rate 82.2 (66.1,98.3) 1.03 <0.001
ART_score → Case_rate -2.9 (-5.7, -0.01) -0.21 0.05
HEI → ART_score 3.7 (2.0, 5.5) 0.64 <0.001
Indirect (mediation) effectb HEI → Case_rate -10.6 (-22.4, 1.2) -0.13 0.077
Total effects HEI → Case_rate 71.6 (57.9, 85.3) 0.90 <0.001
ART_score → Case_rate -2.9 (-5.7, -0.01) -0.21 0.05
HEI → ART_score 3.73 (2.0, 5.5) 0.64 <0.001
b) Linear Regression model
Model predictor outcome Coef (95% CI) Standardized coef. (Adjusted R2) p-value
Simple linear HEI Case_rate 72.8 (57.5, 88.2) 0.90 (0.81)* <0.001
ART_score Case_rate 6.1 (0.92, 11.4) 0.45 (0.17)* 0.023
HEI ART_score 3.4 (1.4, 5.4) 0.60 (0.34)* 0.002
Multiple regression HEI Case_rate 82.8 (64.6, 101.1) 1.03 (0.83a) <0.001
ART_score Case rate -3.0 (-6.2, 0.31) -0.20 0.074
Mediated effectsb HEI Case_rate -10.0 (-21.8, 1.8) >0.05
HEI=Infant HIV exposure, case-rate= number of new paediatric HIV infections per 100 000 live births (paediatric HIV case rate), %MTCT= percent mother to child
transmission of HIV, ART-score=% of HIV on treatment + % HIV-suppressed + % of pregnant women on ART.
a: Adjusted R2 for full multiple regression model b indicated mediated effects *indicates proportion of outcome (out of 1) explained by this variable in simple
linear regression
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[40]. This is especially important given that data from South
Africa show that incident HIV infections amongst pregnant
and breastfeeding women may account for only 7% of all
maternal HIV infections but 26% of MTCT [41]. There has
been dramatic progress in reducing MTCT in SSA follow-
ing the widespread adoption of a ‘universal test and treat’
approach for HIV-positive pregnant and breastfeeding
women [6]. However, the ability of SSA countries to reduce
MTCT further, particularly in breastfeeding countries will
require substantial commitment including addressing the
social and health system barriers to achieving maternal
ART retention and viral suppression throughout pregnancy
and the breastfeeding period (2 years or more in many
countries). In SSA, where resources for health are stretched
across multiple disease areas, scaling up routine viral load
monitoring with urgent interventions for women who are
not suppressed will require additional investments that opti-
mise ART adherence and retention in care [42]. Enhanced
psychosocial support and community engagement to reduce
stigma will also be needed to complement health system
improvements. Qualitative data from South Africa, a Global
Plan priority country, demonstrated that lack of money to
pay for transport, fear of an HIV-positive diagnosis, judge-
mental attitudes of health workers, lack of skilled staff and a
lack of drugs and supplies hinder access to care [43]. Re-
gardless of setting, stigma reduction and normalisation of
HIV as a chronic disease will facilitate access to and uptake
of care: A meta-analysis and systematic review published in
2017 illustrated that stigma reduction strategies have small
effects in improving HIV knowledge and reducing negative
attitudes towards people living with HIV; additionally, they
are more effective amongst professionals, or if multiple ses-
sions are conducted or if programmes are implemented in
community settings [44].
In high HIV prevalence settings, dominated by hetero-
sexual HIV transmission, the case rate could be lowered
by reducing HIV incidence among women of reproductive
age. [45] Antiretroviral use to prevent HIV acquisition in
high risk HIV negative individuals, also known as pre-ex-
posure prophylaxis or PrEP, has demonstrated effective-
ness in at least two large-scale clinical trials, namely
Partners PrEP and iPrEx, but there are no randomised
trials data on its use in pregnant or lactating women
[46, 47]. Partners PrEP enrolled heterosexual sero-dis-
cordant couples in Kenya and Uganda and demonstrated
a 75% reduction in HIV acquisition overall, and a 90% re-
duction in HIV acquisition in participants with detectable
drug in their blood.[47] The partners PrEP study docu-
mented 288 pregnancies exposed to PrEP during the first
few weeks of pregnancy. [48] As per study protocol PrEP
was stopped in these women. Infant follow-up during the
first year of life demonstrated no statistical difference in
adverse infant outcomes. Further study of PrEP during
pregnancy and lactation are ongoing. Although PrEP use
is supported amongst pregnant and lactating women
whose HIV positive partners have unsuppressed viral load
in Australia, Canada, France, New Zealand, the USA and
UK, in SSA, only Kenya, Uganda and eSwatini support
such use in sero-discordant couples. Research is needed to
establish foetal safety, and optimal target group in high
HIV prevalence settings where most pregnant women de-
scribe themselves as single.[49] Whilst these data are
awaited other evidence-based HIV prevention strategies
are needed to reduce HIV incidence in women of repro-
ductive age. These include voluntary medical male cir-
cumcision, which is an effective intervention to reduce
horizontal HIV transmission and offers protection against
cervical cancer, chlamydia and syphilis; however, it offers
little direct control over the risk process to vulnerable, dis-
empowered women [50]. Similar to other researchers, we
believe that multipronged holistic approaches addressing
upstream structural, biomedical, legal, social, gender-re-
lated and health system drivers of HIV incidence are
needed, in addition to biomedical interventions imple-
mented at scale [51–53]. Structural interventions include
sexual and reproductive education amongst adolescents,
young and older women and men, family planning, and
addressing social constructs of masculinity [51]. Such a
holistic prevention framework, which includes supporting
the economic advancement of women, can facilitate self-
protection and HIV avoidance [51, 53]. One potential
success story is the PEPFAR pioneering DREAMS
(Determined, Resilient, Empowered, AIDS-free, Mentored
and Safe) public-private partnership currently imple-
mented in 63 districts within 10 African countries:
DREAMS implements a core package that combines evi-
dence-based approaches within the health sector, with
those that address structural drivers that increase girls’
HIV risk, including poverty, gender inequality, sexual vio-
lence, and a lack of education, and achieved a 25% decline
in new HIV diagnoses amongst girls and young women
aged 15-24 between 2015 and November 2017 [54].
Conclusions
Drawing from the characteristics of EMTCT-validated
countries, we deduce that offering universal ART is just
one important step towards EMTCT validation. Simultan-
eous health system strengthening to improve service
delivery, client tracing, programme monitoring, leadership
and governance, and social, educational and structural
interventions to reduce HIV incidence amongst women of
reproductive age and HIV-related stigma are critical,
potentially modifiable contextual factors that determine
success.
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